The Current Ratio as of November 2024 (TTM) for Monopar Therapeutics Inc. (MNPR) is 5.41K

According to Monopar Therapeutics Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 5.41K. This represents a change of 298.75% compared to the average of 1.36K of the last 4 quarters.

Monopar Therapeutics Inc. (MNPR) Historical Current Ratio (quarterly & annually)

How has MNPR Current Ratio performed in the past?

The mean historical Current Ratio of Monopar Therapeutics Inc. over the last ten years is 17.94. The current 5.41K Current Ratio has changed 3.01% with respect to the historical average. Over the past ten years (40 quarters), MNPR's Current Ratio was at its highest in in the September 2024 quarter at 5.41K. The Current Ratio was at its lowest in in the March 2016 quarter at 0.

Monopar Therapeutics Inc. (MNPR) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Monopar Therapeutics Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Monopar Therapeutics Inc. (MNPR) Average Current Ratio

How has MNPR Current Ratio performed in the past?

The current Current Ratio of Monopar Therapeutics Inc. (MNPR) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Monopar Therapeutics Inc. (MNPR) Current Ratio vs. Peers

How is MNPR’s Current Ratio compared to its peers?

Monopar Therapeutics Inc.’s Current Ratio is greater than Anebulo Pharmaceuticals, Inc. (3.45), greater than Acrivon Therapeutics, Inc. Common Stock (12.75), greater than PMV Pharmaceuticals, Inc. (13.98), greater than Molecular Partners AG (14.33), greater than Mineralys Therapeutics, Inc. (8.55), greater than Candel Therapeutics, Inc. (1.18), greater than Acurx Pharmaceuticals, Inc. (1.74), greater than Enochian Biosciences, Inc. (0.08), greater than scPharmaceuticals Inc. (8.08), greater than DiaMedica Therapeutics Inc. (11.81), greater than Scopus BioPharma Inc. (0.05), greater than Pasithea Therapeutics Corp. (14.81), greater than AN2 Therapeutics, Inc. (9.75), greater than Pharvaris N.V. (19.08), greater than PepGen Inc. (8.47), greater than Aerovate Therapeutics, Inc. (8.78), greater than Adagene Inc. (2.50), greater than Rezolute, Inc. (13.79),

Build a custom stock screener for Monopar Therapeutics Inc. (MNPR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Monopar Therapeutics Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Monopar Therapeutics Inc. (MNPR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Monopar Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.